Shayar: Understanding the Evidence-Based Role of This Traditional Herbal Supplement in Prenatal Wellness

What Is Shayar—and Why Is It Gaining Attention in Prenatal Care?

Shayar is a clinically studied, patented ashwagandha root extract manufactured by Himalaya Drug Company, a WHO-GMP-certified pharmaceutical firm headquartered in Bengaluru, India. Unlike generic ashwagandha powders or tinctures, Shayar is standardized to contain 5% withanolide glycosides—including withaferin A, withanoside IV, and sitoindosides VII–X—as confirmed by high-performance liquid chromatography (HPLC) at Himalaya’s ISO 17025-accredited analytical lab. In 2022, the U.S. FDA granted Shayar GRAS (Generally Recognized as Safe) status for use in dietary supplements at doses up to 300 mg twice daily. Though not approved for use during pregnancy, growing interest stems from three randomized controlled trials involving 412 women with subclinical hypothyroidism, PCOS-related infertility, and stress-induced amenorrhea—all conducted under IRB oversight and published in The Journal of Clinical Endocrinology & Metabolism, Fertility and Sterility, and Complementary Therapies in Medicine. These studies reported statistically significant improvements in serum TSH (mean reduction of 1.8 mIU/L), AMH levels (increase of 1.4 ng/mL), and cortisol AUC (area under the curve) over 12 weeks—with no adverse fetal outcomes reported among participants who conceived during follow-up.

Pharmacological Profile: How Shayar Differs From Other Ashwagandha Preparations

Standardization matters. Most commercial ashwagandha products contain variable concentrations of bioactive withanolides—ranging from 0.1% to 2.5%—due to uncontrolled harvesting, drying methods, and extraction solvents. Shayar uses a proprietary cold-aqueous extraction process that preserves heat-labile glycosides while removing heavy metals (tested to <0.1 ppm lead, <0.05 ppm cadmium per batch) and microbial contaminants (total aerobic count <100 CFU/g). Each 300-mg capsule delivers precisely 15 mg of total withanolide glycosides. In contrast, a widely available brand—Organic India Ashwagandha Root Powder—averages 1.2% withanolides, meaning a 3-g serving yields only ~36 mg total, with highly inconsistent bioavailability due to lack of enteric coating or lipid enhancement.

Bioavailability and Absorption Kinetics

A 2021 crossover pharmacokinetic study in 24 healthy adults (18–45 years, BMI 19–25 kg/m²) demonstrated that Shayar achieves peak plasma concentration (C_max) of withanoside IV at 1.8 ± 0.4 hours post-dose, with an absolute bioavailability of 42.7%—more than double that of non-standardized ethanolic extracts (18.3%, p < 0.001, ANOVA). The elimination half-life was 6.2 ± 0.9 hours, supporting twice-daily dosing. Importantly, co-administration with 10 g of medium-chain triglyceride (MCT) oil increased C_max by 31% and AUC by 27%, suggesting practical formulation synergies for prenatal nutrition planning.

Metabolic Pathways and Enzyme Interactions

Shayar undergoes phase II glucuronidation primarily via UGT1A1 and UGT1A3 enzymes in the liver. In vitro assays using human hepatocytes showed no inhibition of CYP3A4, CYP2D6, or CYP2C9 at concentrations up to 10 µM—well above anticipated systemic exposure (<0.8 µM after 300 mg oral dose). This distinguishes it from alcoholic ashwagandha tinctures, which have demonstrated mild CYP3A4 induction in rodent models and may theoretically reduce efficacy of progesterone-only contraceptives—a critical consideration when counseling patients transitioning off birth control preconception.

Clinical Evidence: What Human Studies Reveal About Safety and Efficacy

The largest prospective trial evaluating Shayar in reproductive-age women was the SHINE-PCOS study (NCT03987245), a 24-week, double-blind, placebo-controlled RCT involving 198 participants diagnosed with Rotterdam criteria-defined PCOS. Participants received either Shayar 300 mg BID or matched placebo. At week 12, the Shayar group showed a mean increase in serum anti-Müllerian hormone (AMH) of +1.42 ng/mL (95% CI: +1.11 to +1.73; p = 0.002), a 22% reduction in Ferriman-Gallwey hirsutism score (p < 0.001), and a 3.1 kg greater mean weight loss versus placebo (p = 0.014). Crucially, 17 women (12.4%) in the Shayar arm conceived spontaneously during the trial period—compared to 4 (2.9%) in placebo—despite identical lifestyle counseling. No congenital anomalies were detected in any newborn (n = 21) through 12-month pediatric follow-up per WHO ICD-11 coding.

Thyroid Function Modulation in Subclinical Hypothyroidism

In the THYRA-SHAYAR trial (n = 112, NCT04123827), women aged 22–38 with TSH 4.0–10.0 mIU/L and normal free T4 received Shayar 300 mg BID or placebo for 16 weeks. By week 8, the Shayar group exhibited a mean TSH decline of −1.83 mIU/L (SD ± 0.67), compared to −0.31 mIU/L in placebo (p < 0.001, intention-to-treat analysis). Notably, 68% of Shayar recipients achieved TSH normalization (<2.5 mIU/L) by week 16, versus 21% in placebo. Free T3 and free T4 remained within reference ranges throughout, confirming non-toxic modulation rather than overstimulation. Given that maternal TSH >2.5 mIU/L in early pregnancy correlates with 2.3× higher risk of miscarriage (per 2023 Endocrine Society Clinical Practice Guideline), this effect warrants careful discussion during preconception visits.

Stress Biomarkers and Autonomic Balance

A third trial—STRESS-PREG (NCT04552210)—enrolled 102 women with self-reported chronic stress (Perceived Stress Scale ≥20) undergoing fertility treatment. Participants received Shayar 300 mg BID or placebo for 10 weeks prior to embryo transfer. Salivary cortisol measured at awakening, 30 min post-awakening (CAR), and bedtime revealed that the Shayar group had a significantly flattened diurnal slope (−0.18 nmol/L/h vs. −0.09 in placebo; p = 0.007) and reduced CAR magnitude (Δ = +4.2 nmol/L vs. +7.9 nmol/L; p = 0.02). Heart rate variability (HRV) analysis via wearable ECG (Biostrap EX) showed 19% higher RMSSD (root mean square of successive differences) in the Shayar group at week 10—a marker of enhanced parasympathetic tone linked to improved uterine artery blood flow velocity in Doppler studies.

Regulatory Status and Quality Assurance Across Markets

Himalaya manufactures Shayar in its WHO-GMP-certified facility in Bangalore, subject to annual audits by the Indian Ministry of AYUSH and voluntary third-party verification by NSF International. Every batch undergoes full Certificate of Analysis (CoA) testing for: (1) withanolide glycoside profile (HPLC); (2) heavy metals (ICP-MS); (3) pesticide residues (GC-MS/MS per EPA Method 1694); (4) microbiological purity (USP <61> and <62>); and (5) absence of adulterants like sudemycin or shilajit. Batch-specific CoAs are publicly accessible via Himalaya’s online portal using the 12-digit lot number printed on each bottle. For comparison, a 2022 independent analysis by ConsumerLab.com found that 37% of 42 commercially available ashwagandha supplements failed label claims for withanolide content, and 12% exceeded California Proposition 65 limits for lead.

Integrative Use During Preconception and Early Pregnancy: Practical Protocols

While Shayar is not FDA-approved for use during pregnancy, evidence supports cautious, time-limited use in the preconception window (typically defined as 3–6 months prior to conception attempt) under collaborative care. Key parameters include baseline thyroid panel (TSH, free T4, TPO antibodies), AMH, and salivary cortisol rhythm assessment. Dosing should begin at 150 mg once daily for 7 days, then escalate to 300 mg once daily for 7 days, before reaching the standard 300 mg BID protocol. Discontinuation is recommended immediately upon positive urine hCG test or clinical confirmation of pregnancy—consistent with guidelines from the American College of Nurse-Midwives (ACNM) Position Statement on Herbal Use in Pregnancy (2021).

Contraindications and Red-Flag Conditions

Shayar is contraindicated in individuals with: (1) known hypersensitivity to Solanaceae family plants (e.g., tomato, potato, eggplant); (2) active autoimmune thyroid disease with TPO antibody titers >1,000 IU/mL; (3) current use of antithyroid medications (methimazole, propylthiouracil); or (4) history of recurrent miscarriage with documented thrombophilia (Factor V Leiden, prothrombin G20210A mutation). Case reports describe transient elevation of liver transaminases (ALT >2× ULN) in two individuals with preexisting NAFLD consuming >600 mg/day for >8 weeks—underscoring the importance of hepatic screening (AST, ALT, GGT) prior to initiation.

Interactions With Common Prenatal Nutrients

No clinically relevant interactions have been documented between Shayar and iron bisglycinate (up to 27 mg elemental Fe), methylfolate (800 mcg), or vitamin D3 (2,000 IU). However, concurrent use with high-dose zinc (>30 mg elemental Zn) may reduce Shayar absorption by up to 34% in vitro due to competitive binding at intestinal metal transporters (ZIP4). We recommend separating Shayar and zinc supplementation by at least 3 hours. Magnesium glycinate (200 mg elemental Mg) appears synergistic—enhancing GABA-A receptor affinity in preclinical models—and is safely co-administered.

Navigating Patient Questions: Evidence-Based Talking Points

Pregnant and preconception patients frequently ask whether Shayar is ‘natural’ and therefore safe. As a doula and prenatal educator, I emphasize that ‘natural’ does not equal ‘risk-free’—just as oxytocin is endogenous yet requires strict dosing protocols in labor. I share concrete data: in the SHINE-PCOS trial, 12.4% conception rate with Shayar versus 2.9% with placebo translates to a number-needed-to-treat (NNT) of 11 to support one additional conception. That compares favorably to clomiphene citrate (NNT = 9–12) but without associated hot flashes or thin endometrial lining. I also clarify that Shayar does not act as a direct fertility drug—it modulates hypothalamic-pituitary-adrenal-thyroid-ovarian axes to restore homeostasis, making it most effective in functional imbalances rather than anatomical barriers like tubal occlusion or severe male factor infertility.

Risk-Benefit Assessment: A Structured Framework for Shared Decision-Making

We use a structured 4-quadrant framework during prenatal education sessions:

1. Documented Benefits: TSH normalization in subclinical hypothyroidism (RR = 3.2, 95% CI 2.1–4.8); AMH improvement in PCOS (mean +1.4 ng/mL); cortisol rhythm stabilization (CAR reduction 47%); HRV enhancement (+19% RMSSD)
2. Known Risks: Mild GI discomfort (5.3% incidence, mostly bloating in first 3 days); rare transient ALT elevation in preexisting liver disease; theoretical concern for uterine stimulation at >600 mg/day (not observed in human trials but noted in murine myometrial tissue assays at 10 µM concentration)
3. Uncertainties: Long-term neurodevelopmental outcomes in offspring (no data beyond 12 months); impact on placental 11β-HSD2 enzyme activity (in vitro IC₅₀ = 8.7 µM, far exceeding physiological exposure)
4. Alternatives: Selenium 200 mcg/day (for TPO+ patients), cognitive behavioral therapy for stress (per Cochrane review), or metformin 500 mg BID (for PCOS with insulin resistance)

This framework anchors conversations in measurable metrics—not anecdotes or tradition alone. It also aligns with the American Academy of Pediatrics’ 2022 guidance on shared decision-making in perinatal integrative care, which recommends documenting patient values, clinical evidence strength, and explicit agreement on monitoring parameters.

Quality Control Metrics: Comparing Shayar Against Industry Benchmarks

Below is a comparative analysis of key quality indicators across leading ashwagandha products tested in 2023 by the independent laboratory Eurofins Scientific (report #EC-ASH-2023-0887). All values represent batch-average results across 10 randomly selected units per product.

Notably, both Shayar and KSM-66 meet USP monograph standards for ashwagandha, but only Shayar provides batch-specific CoAs with HPLC chromatograms publicly accessible online. Organic India and Garden of Life report average values only in marketing materials—without lot traceability. This transparency directly impacts clinical confidence when recommending supplementation during sensitive windows like preconception.

From a public health perspective, integrating evidence-based botanicals like Shayar into prenatal education requires humility, precision, and accountability. It means distinguishing between traditional use and clinical validation—acknowledging that centuries of Ayurvedic practice informed the hypothesis, but only rigorous modern trials provide actionable thresholds for safety and timing. As doulas and educators, our role isn’t to endorse or dismiss—but to translate complex data into personalized, values-aligned decisions grounded in physiology, not ideology.

For clinicians and birth workers, this includes verifying manufacturer certifications (look for WHO-GMP, ISO 17025, NSF registration), requesting CoAs before recommending any supplement, and documenting shared decision-making conversations using standardized templates aligned with ACNM and ACOG documentation standards. Patients deserve clarity—not certainty—and that begins with naming what we know, what we suspect, and what remains unknown.

Shayar represents a paradigm shift: not as a replacement for conventional care, but as a physiologically targeted adjunct with measurable biomarker effects. Its value lies not in mystique, but in milligrams, micromoles, and meticulously collected outcome data. When used intentionally, transparently, and temporarily—within the preconception window—it may help restore foundational endocrine balance, giving pregnancy its best possible physiological starting point.

One final note: never assume patient familiarity with terms like ‘withanolides’ or ‘AUC.’ Always define acronyms at first use and anchor explanations in tangible outcomes—‘This means your morning cortisol spike decreased by nearly half, which helps your body shift out of constant alert mode and into rest-and-restore—exactly what your reproductive system needs to function optimally.’ Clarity is clinical care.

As of April 2024, Himalaya reports global distribution of Shayar across 32 countries, with prescription requirements in Germany and Japan, and OTC availability in Canada, Australia, and the United States. Pricing averages $42.99 for a 60-capsule bottle (30-day supply at 300 mg BID), covered under some employer-sponsored FSA/HSA plans when prescribed for thyroid or stress-related indications with appropriate diagnostic codes (ICD-10: E03.9 for hypothyroidism, F43.21 for adjustment disorder with anxiety).

For continued learning, refer to the open-access SHINE-PCOS trial manuscript (DOI: 10.1210/clinem/dgab892), the Himalaya Shayar Product Monograph (v4.2, March 2024), and the National Center for Complementary and Integrative Health’s 2023 Ashwagandha Fact Sheet (NCCIH Publication No. D385).

Always consult current state and federal regulations—such as the Texas Board of Midwifery’s 2023 Advisory Opinion #TX-MW-2023-07 on herbal supplement disclosure—before incorporating any botanical into your scope of practice. Documentation must include rationale, dosage, duration, contraindications reviewed, and patient acknowledgment of uncertainties.

Ultimately, supporting families through preconception is about optimizing conditions—not controlling outcomes. Shayar, when understood and applied with scientific rigor, may be one evidence-informed tool toward that goal. Its power resides not in promise, but in precision.